Abstracts

746 – Global Analysis of COVID-19 Symptom Burden and Treatment Perceptions Among the Medically Vulnerable

Background Medically vulnerable individuals with pre-existing comorbidities remain at heightened risk of severe COVID-19 disease and outcomes. To better understand the post-pandemic impact of COVID-19 on this population, the COVID Community Council (eight representatives from global medically vulnerable patient organizations) co-created the ‘Attitudes about COVID and Community Engagement with Patients’ (ACCEPt) global survey. Methods ACCEPt…

785 – Effect of Metformin on the PopPK of Rifampicin, Isoniazid, and Pyrazinamide in Adults With TB/HIV

Background Tuberculosis (TB) remains the leading infectious cause of death, especially in people with HIV. Metformin is a promising immunometabolic host-directed therapy that might improve TB treatment. However, drug-drug interactions should be considered when including metformin in the current TB and HIV treatment regimens. Metformin has been reported to lower rifampicin and isoniazid exposure. In…

821 – Timing of Dolutegravir Initiation and Birth Outcomes Among Pregnant Women Living With HIV in Kenya

Background The effect of antiretroviral therapy (ART) initiation before conception and at different stages of gestation on adverse perinatal outcomes remains uncertain, as existing studies yield conflicting results. Few studies evaluate how the timing of dolutegravir (DTG)-based ART initiation during pregnancy affects perinatal outcomes. Methods We analyzed data from pregnant women living with HIV (WLHIV)…

284 – Lactobacillus Vaginal Microbiome Associates With Increased Immunity and HIV Vaccine Responses

Background New vaccine strategies against HIV should induce protective mucosal immune response in the female genital tract which is a first site of virus acquisition. The microbiome has been implicated in altered mucosal immunity, but its impact on vaccine-induced mucosal responses in the genital tract is not well understood.  Methods Cervicovaginal mucus samples were collected…

297 – Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI

Background Beyond their neutralization activity, bNAbs may enable post-treatment control of HIV by promoting effective endogenous HIV-specific immune responses via HIV:bNAb immune complexes (the vaccinal effect). In the UCSF-amfAR combination immunotherapy trial (NCT04357821), 10 participants with HIV on antiretroviral therapy (ART) received interventions including infusions of two bNAbs (10-1074 & VRC07-523LS), the second just before…

357 – Immune Clearance Proteomic Signatures and Efavirenz Linked to Lower Completed HIV Transcript Levels

Background Incomplete HIV transcripts far outnumber completed or spliced HIV RNA in ART-suppressed PWH, but it is not clear which HIV transcripts are associated with immune activation and/or immune clearance markers in this setting.  Efavirenz (EFV) may induce pyroptosis of HIV-expressing cells, but its relationship to HIV transcriptional activity is also unclear. Methods We measured…

1113 – A Roadmap to New Models for Long-Acting Injectable Antiretroviral Administration

Background Long-acting cabotegravir and rilpivirine (LA CAB/RPV) is injected intramuscularly typically by a nurse in clinic. As more people with HIV (PWH) are switching to long-acting injectable (LAI) antiretroviral therapy (ART), expanding access through different models of care is needed. Perspectives from PWH on in clinic administration of LA CAB/RPV could provide critical insight to…

663 – Association of Trimethylamine N-Oxide and Cardiovascular Disease in People With and Without HIV

Background Understanding how HIV contributes to excess cardiovascular disease (CVD) risk beyond traditional CVD risk factors is important to identify interventions to reduce CVD risk for people with HIV (PWH). Microbiome dependent metabolites may represent novel modifiable biomarkers of CVD risk PWH. Alterations in gut microbial composition may affect the production of microbiome dependent metabolites like…